Invitae : Ciitizen Announcement Conference Call Presentation

+

From genetics, health

Acquisition and platform update 09 | 07 | 21

Safe harbor statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding the potential benefits of its pending acquisition of Ciitizen; the expected transaction terms; the company's beliefs regarding its business and business strategy; and the benefits and importance of the company's acquisitions and collaborations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the closing of the pending acquisition of Ciitizen; the ability of the company to achieve the expected benefits of the acquisition; the impact of COVID- 19 on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the company's ability to continue to grow its business, including internationally; the ability to maintain important customer relationships; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's ability to obtain regulatory approval for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; the applicability of clinical research results to actual outcomes; the success of collaborations; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

© 2021 Invitae Corporation. All Rights Reserved.

2

Single greatest shift in medicine and healthcare

"Modern" medicine

Chemotherapy standard of care Newborn diagnosis after birth

Symptom-based, universally applied

© 2021 Invitae Corporation. All Rights Reserved.

Universal testing for all

Risk information = effective prevention

Earliest detection - disease eradication

Personalized therapy and biomarker driven monitoring

Gene informed healthcare throughout life

3

Invitae's mission and core data tenets

Patients own	Health data
is more
their health
valuable
data
when shared

© 2021 Invitae Corporation. All Rights Reserved.

4

1. patient-mediatedplatform for data sharing

1. patient-mediated platform that allows patients to collect and store their medical records, and turns documents into usable, computable and relevant longitudinal data that can be shared with whomever they consent

© 2021 Invitae Corporation. All Rights Reserved.

5